Cycloserine Medical Insurance Reimbursement Policy and Conditions

Cycloserine (Cycloserine) is a second-line anti-tuberculosis drug mainly used to treat multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Due to its unique mechanism of action, it can effectively inhibit the cell wall synthesis of Mycobacterium tuberculosis and is currently one of the important drugs recommended by the World Health Organization (WHO) for the treatment of drug-resistant tuberculosis.

In China, with the emphasis on drug-resistant tuberculosis and the upgrading of prevention and control strategies, cycloserine has been included in the national medical insurance drug catalog and classified as a Class B drug. However, at the level of actual medical insurance reimbursement, there are large differences between different regions, which are mainly affected by local medical insurance policies, hospital levels and drug dispensing channels. Generally speaking, the medical insurance payment ratio for Class B drugs varies according to specific regional policies. Patients need to bear a certain proportion of self-pay, usually 10%-30%, and the rest is paid by the basic medical insurance fund.

It is worth noting that cycloserine cannot be purchased freely in conventional pharmacies. It must be reasonably prescribed by a qualified tuberculosis specialist hospital based on the drug resistance test results and the national standard anti-tuberculosis treatment plan. Strict blood concentration monitoring and mental status assessment must be carried out during the treatment period. Some regional medical insurance departments have also established"anti-tuberculosis disease reimbursement channel", which may provide a higher proportion of special fund subsidies to patients who pass the national free tuberculosis program screening and meet the diagnostic criteria for drug-resistant tuberculosis

Therefore, it is recommended that patients go to the local designated tuberculosis hospital for evaluation before using cycloserine, and consult the local medical insurance bureau or the medical insurance office of the designated hospital to understand the specific reimbursement policy, declaration process and required materials for this drug in their area to obtain more clear and comprehensive protection. With the continuous advancement of tuberculosis prevention and control in China, the medical insurance accessibility of cycloserine is also expected to be further optimized.

Reference materials:https://en.wikipedia.org/wiki/Cycloserine